Literature DB >> 24053401

Adjuvanted influenza vaccines.

Orli Even-Or1, Sarit Samira, Ronald Ellis, Eli Kedar, Yechezkel Barenholz.   

Abstract

Influenza is one of the most common causes of human morbidity and mortality that is preventable by vaccination. Immunization with available vaccines provides incomplete protection against illness caused by influenza virus, especially in high-risk groups such as the elderly and young children. Thus, more efficacious vaccines are needed for the entire population, and all the more so for high-risk groups. One way to improve immune responses and protection is to formulate the vaccine with antigen carriers and/or adjuvants, which can play an important role in improving immune responses and delivery to antigen-presenting cells, especially for a vaccine like influenza that is based on protein antigens usually administered without a carrier or adjuvant. In this review, the authors present an overview of available vaccines, focusing on research and development of new adjuvants used in influenza vaccines, as well as adjuvanted influenza vaccines aimed to improve immune responses, protection and breadth of coverage for influenza.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24053401     DOI: 10.1586/14760584.2013.825445

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  16 in total

1.  Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.

Authors:  Shahla Shahsavandi; Mohammad Majid Ebrahimi; Kaveh Sadeghi; Homayoon Mahravani
Journal:  Virol Sin       Date:  2015-04-15       Impact factor: 4.327

Review 2.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

Review 3.  Infants and the seasonal influenza vaccine. A global perspective on safety, effectiveness, and alternate forms of protection.

Authors:  Leah F Moriarty; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  In Silico Analysis of HA2/Mx Chimera Peptide for Developing an Adjuvanted Vaccine to Induce Immune Responses Against Influenza Viruses.

Authors:  Sina Soleimani; Omid Madadgar; Shahla Shahsavandi; Homayoon Mahravani; Mohsen Lotfi
Journal:  Adv Pharm Bull       Date:  2015-12-31

5.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

6.  Characterization of Immune Response towards Generation of Universal Anti-HA-Stalk Antibodies after Immunization of Broiler Hens with Triple H5N1/NA-HA-M1 VLPs.

Authors:  Beata Gromadzka; Milena Chraniuk; Lilit Hovhannisyan; Karolina Uranowska; Bogusław Szewczyk; Magdalena Narajczyk; Mirosława Panasiuk
Journal:  Viruses       Date:  2022-03-30       Impact factor: 5.818

7.  Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor.

Authors:  Joanna A Pulit-Penaloza; Bishu Sapkota; E Stein Esser; Richard W Compans; Brian P Pollack; Ioanna Skountzou
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

Review 8.  New vaccines against influenza virus.

Authors:  Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Yu-Na Lee; Min-Chul Kim; Young-Man Kwon; Yinghua Tang; Min-Kyoung Cho; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18

9.  System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test.

Authors:  Takuo Mizukami; Haruka Momose; Madoka Kuramitsu; Kazuya Takizawa; Kumiko Araki; Keiko Furuhata; Ken J Ishii; Isao Hamaguchi; Kazunari Yamaguchi
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

10.  Editorial: Influenza Virus Vaccines and Immunotherapies.

Authors:  Arun Kumar; Shakti Singh
Journal:  Front Immunol       Date:  2015-11-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.